CURX (Curanex Pharmaceuticals) Earnings per share for the last four quarters

Curanex Pharma (CURX) - corporate logo

This chart of EPS (TTM) value changes on the GURU.Markets platform for Curanex Pharmaceuticals Inc (CURX) is -836.50. Curanex Pharmaceuticals Inc (CURX) aims to outperform its capital rivals in biomarker validation. The business is vulnerable to component supply chain disruptions and complexities regarding international software patenting. Success depends on recognition from gastroenterologists and reaching critical milestones in the development of digestive organ medications.

Curanex Pharmaceuticals Inc (CURX) Net earnings per share for the last 12 months: for the period 11/23/2025 - 11/18/2026

Curanex Pharmaceuticals Inc - analytical breakdowns and key metrics (CURX)

- market price and analyst price targets:
- business market valuation indicators:
Initial company analysis:Curanex Pharma, CURX
Product sample of Curanex

For Curanex Pharmaceuticals Inc (CURX), expansion into the GI segment and the development of the drug pipeline are directly reflected in the EPS YoY (TTM) percentage growth history, which visualizes the earnings per share trend. This indicator compares current net income with the same period last year while accounting for currency fluctuations, allowing investors to assess the real efficiency of business scaling and avoid overpaying for the asset.